EUCTR2011-000460-10-IT进行中（未招募）不适用
First year growth response associated genetic markers validation Phase IV open-label study in Growth Hormone Deficient and Turner Syndrome pre-pubertal children : the PREDICT Pharmacogenetics Validation Study - PREDICT PGx Validation Study
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 395
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Pre-established diagnosis of IGHD or TS based on classical criteria with at least 1 year of r-hGH therapy and with Tanner stage 1 at treatment start 2) Retrospective availability of a complete set of clinical, auxological and biological parameters necessary for building the predictive model
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 350
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 45
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Acquired GHD 2) Any drug or disease that could affect growth
研究者
相似试验
进行中（未招募）
1 期
Validation study for genetic markers for growth hormone treatment in growth hormone deficient and turner syndrome patientsEUCTR2011-000460-10-ESMerck Serono S.A. Geneva461
进行中（未招募）
不适用
Validation study for genetic markers for growth hormone treatment in growth hormone deficient and turner syndrome patientsEUCTR2011-000460-10-GBMerck Serono SA395
进行中（未招募）
不适用
Validation study for genetic markers for growth hormone treatment in growth hormone deficient and turner syndrome patientsIdiopathic Growth Hormone Deficiency and Turner SyndromeMedDRA version: 13.1Level: PTClassification code 10056438Term: Growth hormone deficiencySystem Organ Class: 10014698 - Endocrine disordersMedDRA version: 13.1Level: PTClassification code 10045181Term: Turner's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-000460-10-CZMerck Serono S.A. Geneva395
进行中（未招募）
1 期
Pilot study for evaluation of growth factor erythropoietin beta for improvement of left ventricular function after coronary interventions - EPO in ischemic heart failureIschemic heart failure is a major public health burden in western societies. Although technical advancements have improved recascularization of ischemic heart tissue in recent years, data on functional improvement concerning the left ventricle suggest a need for optimization of pharamcological therapie. The growth hormone erythropoietin beta has been shown to improve heart function in various animal models of ischemic heart disease.EUCTR2004-002646-35-DEFranz Volhard Clinic, Charite Campus Buch60
已完成
3 期
Sub-study on genetic markers responsible to effects of HMG-CoA reductase inhibitor preventing recurrence of strokeIschemic strokeJPRN-UMIN000008055Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences1,000